Chinese herbal medicine (Bu-Shen-Tian-Jing Formula) for outcomes of IVF in Chinese patients with polycystic ovary syndrome: A retrospective cohort study

Pan, Xiaoming; Gu, Ying‐Er; Zhang, Xian; Shi, Biwei; Cui, Long; Wang, Fangfang; Qu, Fan

doi:10.1016/j.imr.2021.100775

Cited by 9 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2021 ; Pan et al. 2022 ). To determine the appropriate concentrations of BSTJF1 and BSTJF2 and evaluate their cytotoxicity in KGN cells, we conducted a CCK8 assay with freeze-dried powder at different concentrations.…”

Section: Resultsmentioning

confidence: 99%

“…(Oleaceae) 20 g and Rubus chingii Hu (Rosaceae) 10 g. BSTJF1 has been reported to help patients with PCOS acquire more retrieved oocytes and increased fertilized oocytes, as well as a higher clinical cumulative pregnancy rate, live birth rate, and term delivery rate (Pan et al. 2022 ). These optimized curative effects may be related to the downregulation of high anti-Müllerian hormone levels in follicular fluids (Pan et al.…”

Section: Introductionmentioning

confidence: 99%

“…These optimized curative effects may be related to the downregulation of high anti-Müllerian hormone levels in follicular fluids (Pan et al. 2022 ). Animal studies have shown that BSTJF1 effectively improves ovarian follicle development in PCOS rats and reduces swollen mitochondria, ruptured mitochondrial cristae, and rough endoplasmic reticulum in progeny born to the BSTJF1 group (Zhang et al.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bu-Shen-Tian-Jing formulas alleviate the mitochondrial damage induced by oxidative stress in ovarian granulosa cells exposed to DEHP through the HDAC3-HSP90AA pathway

Zhang,

Wang,

Zhang

et al. 2023

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

Context di-(2-Ethylhexyl) phthalate (DEHP) has potential reproductive toxicity. Bu-Shen-Tian-Jing formulations (BSTJFs) are beneficial for female reproductive capacity. However, BSTJF2 has much lower cytotoxicity than BSTJF1. Objective To investigate the effects of BSTJFs on ovarian granulosa cells exposed to DEHP and determine the potential molecular mechanisms. Methods and materials Human granulosa-like tumor cell line (KGN) cells were divided into control, DEHP, BSTJF1 and BSTJF2 groups. The DEHP group were given 1 μM DEHP for 24 h. They were then given BSTJF1 at 200 μg/mL or BSTJF2 at 100 μg/mL for 24 h. The control group was treated with the same concentration of DMSO (0.1%). Oxidative stress and mitochondrial function were measured. The mRNA and protein expression levels of HDAC3 and HSP90AA were determined. Integrative network pharmacology analysis of BSTJF2 was also performed. Results DEHP (1 μM) significantly suppressed the proliferation of KGN cells by 17%, significantly increased ROS levels by 28% and MDA levels by 47%, significantly decreased MMP levels by 22% and mtDNA copy by 30%. DEHP significantly increased protein expression of HDAC3 by 21%and HSP90AA by 64%. All these changes were significantly reversed by BSTJFs. Integrative network pharmacology analysis revealed HSP90AA was a key target (degree = 8). Both RGFP966 and BSTJF2 significantly reversed the increased expression of HDAC3 and HSP90AA, attenuated oxidative stress, and mitochondrial damage which were induced by DEHP. Conclusion BSTJFs might have therapeutic potential on oxidative stress and mitochondrial damage through the HDAC3/HSP90AA pathway which encourages further clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bu-Shen-Tian-Jing formulas alleviate the mitochondrial damage induced by oxidative stress in ovarian granulosa cells exposed to DEHP through the HDAC3-HSP90AA pathway

Zhang,

Wang,

Zhang

et al. 2023

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most patients (62.9%) enrolled in our study underwent ovarian stimulation for IVF through an antagonist controlled ovarian hyperstimulation (COH) protocol, while 25.8% received a long agonist protocol, and 11.3% underwent the progestin-primed ovarian stimulation scheme or other protocols. The COH protocol has been described in previous studies (24)(25)(26).…”

Section: Ivf Proceduresmentioning

confidence: 99%

Overweight and obesity determined by body mass index criteria for Asian populations adversely affect assisted reproductive outcomes among Chinese women with polycystic ovary syndrome

Zhao,

Yang,

Cui

et al. 2023

Int J Obes

Self Cite

View full text Add to dashboard Cite

Background: Obesity is a common feature in women with polycystic ovary syndrome (PCOS) and associated with multiple adverse reproductive outcomes. However, the impact of overweight and obesity on reproductive outcome of PCOS women underwent the in vitro fertilization-embryo transfer (IVF-ET) is currently controversial. Since appropriate body mass index (BMI) levels differ across ethnic groups, this study was performed to investigate the effects of BMI on IVF outcomes among women with PCOS using BMI cut-off values proposed by the World Health Organization for Asian populations.Method(s): This was a retrospective study including 1066 women with PCOS receiving IVF treatment at our institution between January 2018 and June 2021, among whom 960 underwent their rst fresh or frozen embryo transfer. Participants were categorized according to their BMI as follows: patients with normal weight (BMI < 23 kg/m 2 ), patients with overweight (BMI: 23-24.9 kg/m 2 ), and patients with obesity (BMI ≥ 25 kg/m 2 ). The effect of BMI on IVF outcomes (the numbers of oocytes, two pronuclear zygotes, and good-quality embryos; the rates of implantation, miscarriage, clinical pregnancy and live birth) was evaluated by descriptive statistics and logistic regression models with confounders adjusted. Interventions: noResult(s): High BMI was associated with signi cantly lower numbers of total oocytes retrieved, mature oocytes, two pronuclear zygotes, and good-quality embryos among women with PCOS. PCOS patients with a BMI ≥ 23 kg/m 2 had signi cantly lower live birth rates (41.9% vs. 49.1%; adjusted odds ratio [aOR], 0.75; 95% con dence interval [CI], 0.57-0.97) and implantation rates (35.8% vs. 43.9%; aOR, 0.76; 95% CI, 0.61-0.93) than those with normal BMI. Conclusion(s): PCOS patients with a BMI ≥ 23 kg/m 2 have lower live birth rates than those with a BMI < 23 kg/m 2 . De ning obesity and overweight with ethnicity-speci c BMI cut-offs may help to improve IVF outcomes among PCOS patients. a, Models were adjusted for age, basal FSH level, the number of transferred embryos, and the type of embryo transfer.

show abstract

“…This included a higher number of retrieved and fertilized oocytes, increased pregnancy rates, and decreased anti-Müllerian hormone (AMH) levels in follicular fluids, without affecting fertilization rates or increasing complications. 25 However, their long-term benefits in reducing CHD risk in patients with PCOS remain largely unexplored.…”

Section: Introductionmentioning

confidence: 99%

Integrated Chinese and Western Medicine for Coronary Heart Disease Prevention in Polycystic Ovary Syndrome: A 19-Year Nationwide Cohort Study

Liao,

Chien,

et al. 2023

JMDH

View full text Add to dashboard Cite

Background Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Chinese herbal medicine (CHM), a major branch of traditional Chinese medicine, has been reported to exert beneficial effects on PCOS symptoms. However, the relationship between CHM use and the risk of coronary heart disease (CHD) in patients with PCOS remains unclear. The study aimed to investigate the potential protective role of CHM on CHD incidence in patients with PCOS and to understand CHM prescription patterns for PCOS treatment. Methods This retrospective cohort study was performed using data from Taiwan’s Longitudinal Health Insurance Database 2000 (LHID2000). Patients with PCOS were identified, and data on their demographic characteristics, comorbidities, and medication use were extracted. The patients were then divided into CHM and non-CHM users. Results Propensity score matching yielded two balanced cohorts of 2913 individuals each. CHM users demonstrated a 94% reduced risk of CHD compared to non-CHM users (adjusted hazard ratio, 0.06; 95% confidence interval, 0.04–0.1) during the 19-year follow-up period. Stratified analysis confirmed the benefits of CHM treatment on the incidence of CHD across various subgroups. The key elements identified in the CHM prescription patterns associated with reduced CHD risk were Xiang Fu, Yi Mu Cao, Jia Wei Xiao Yao San, and Gui Zhi Fu Ling Wan. Conclusion This study provides evidence that CHM may protect against CHD development in patients with PCOS. It is also highlight the most frequently prescribed CHM for mitigating CHD risk among patients with PCOS. These findings lay the groundwork for future studies to confirm and elucidate CHM’s therapeutic mechanisms in PCOS-related CHD prevention, offering a significant contribution to the field.

show abstract

Chinese herbal medicine (Bu-Shen-Tian-Jing Formula) for outcomes of IVF in Chinese patients with polycystic ovary syndrome: A retrospective cohort study

Cited by 9 publications

References 31 publications

Bu-Shen-Tian-Jing formulas alleviate the mitochondrial damage induced by oxidative stress in ovarian granulosa cells exposed to DEHP through the HDAC3-HSP90AA pathway

Bu-Shen-Tian-Jing formulas alleviate the mitochondrial damage induced by oxidative stress in ovarian granulosa cells exposed to DEHP through the HDAC3-HSP90AA pathway

Overweight and obesity determined by body mass index criteria for Asian populations adversely affect assisted reproductive outcomes among Chinese women with polycystic ovary syndrome

Integrated Chinese and Western Medicine for Coronary Heart Disease Prevention in Polycystic Ovary Syndrome: A 19-Year Nationwide Cohort Study

Contact Info

Product

Resources

About